$MCK

Lau Michele sold $2.7M of MCK

Lau Michele (EVP and Chief Legal Officer) sold 3,550 shares of MCKESSON CORP (MCK) at $761.09 ($2.70M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lau Michele
Published May 27, 2026, 6:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 6:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MCK
Neutral
high confidence
Mentioned
$MCK
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MCKNeutralLow
01

Why it matters

Because the trade is pre-scheduled, it is less likely to be a real-time signal about near-term fundamentals; expect muted market reaction absent other news.

02

Market read

Insider selling disclosure with 10b5-1 reduces catalyst value; likely limited trading impact for MCK.

03

What to watch

The sale size ($2.70M) and post-transaction holdings (3,247 shares) may be consistent with routine diversification rather than a thesis change.

Relevance 7/10Timing: Immediate (filed today) but informationally limited; more useful for monitoring insider activity trends than for catalysts.

Background

SEC Form 4 reports insider trades; this one is an open-market sale by McKesson’s EVP and Chief Legal Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

McKesson disclosed an EVP/Chief Legal Officer open-market sale of 3,550 shares ($2.70M) under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely noise unless accompanied by other fundamental news.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged 10b5-1 plan, which generally reduces interpretive value for near-term price direction.

Market effects

Minimal; this is company-specific insider liquidity/compensation activity with no stated operational or regulatory change.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still reflect internal caution; traders may watch for clustering of sales around specific events.

Key entities

  • MCKESSON CORP

    Subject of the Form 4 insider transaction disclosure.

  • Lau Michele

    EVP and Chief Legal Officer who sold 3,550 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.

$MCKHighAI 9/10

McKesson & CD&R Acquire Leading US Home-Infusion Platform

McKesson and private equity firm CD&R will acquire Option Care Health, a US home-infusion care provider, for $5.8bn. CD&R will take a majority stake, while McKesson invests $1.4bn for a minority stake. The deal values Option Care Health at $32.05 per share and is expected to close in H1 2027. McKesson aims to leverage the acquisition to expand its specialty care offerings.

$OPCHHighAI 9/10

Option Care stock surges on McKesson's home-infusion bet

Option Care Health (OPCH) shares rose 33% to $31.11 after McKesson (MCK) and Clayton, Dubilier & Rice agreed to take it private for $32.05 per share, valuing it at $5.8B. McKesson will initially own 49%, with an option to acquire the rest later. The deal gives McKesson access to Option Care's home-infusion network, serving 315K+ patients. Option Care's Q2 revenue grew 1.9% to $1.44B. The deal needs shareholder and regulatory approvals to close in early 2027.

$MCKHighAI 9/10

McKesson Plans $1.4 Billion Stake in $5.8 Billion Option Care Buyout

McKesson plans a $1.4B investment for a 49% stake in Option Care Health, part of a $5.8B buyout by Clayton, Dubilier & Rice. Shareholders will receive $32.05 per share. The deal, pending approvals, is expected to close in early 2027. Option Care shares rose 32.7% on the news. McKesson's Q1 revenue grew 8% to $105.4B, with net income down 22% to $614M.